HCS/HBs 593 & 695 - This act establishes the Missouri Oral Chemotherapy Parity Interim Committee to study the disparity in patient co-payments between orally and intravenously administered chemotherapies, the reasons for the disparity, and the patient benefits in establishing co-payment parity between oral and infused chemotherapy agents. The committee must consider information on the costs or actuarial analysis associated with the delivery of patient oncology treatments. The conclusions of the study must satisfy any statutorily required actuarial analysis. Under the act, the committee is comprised of 16 members, including 4 legislators and the director of the Department of Insurance, Financial Institutions and Professional Registration who is the chair of the committee. All members, except for the members from the General Assembly, are to be appointed by the Governor by September 1, 2013. The department must provide assistance to the committee. By January 1, 2014, the committee must submit a report to the Governor, Speaker of the House of Representatives, President Pro Tem of the Senate, and the appropriate legislative committees of the General Assembly regarding the results of the study and any legislative recommendations. STEPHEN WITTE
|